Clinical Trial Update: Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study NCT00080080 evaluating talabostat in combination with docetaxel in advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Talabostat (talabostat)

Snippet

Sponsor: Point Therapeutics | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED